Please ensure Javascript is enabled for purposes of website accessibility

Acadia Leaps Toward the Finish Line

By Dave Williamson - Apr 11, 2013 at 6:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of Acadia Pharmaceuticals exploded today. What's behind this stock price skyrocket?

After an incredible performance in late March, when shares of Acadia Pharmaceuticals (ACAD 2.56%) jumped up 23%, they have once again exploded today, up 40% intraday. What's behind these massive leaps for this pharmaceutical company, and is there more on the way? In this video, Motley Fool health-care analyst David Williamson tells investors about the drug that has Acadia investors so excited, why it has so many competitive advantages, and what investors need to watch from here.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Acadia Pharmaceuticals Stock Quote
Acadia Pharmaceuticals
$17.02 (2.56%) $0.42
Pfizer Inc. Stock Quote
Pfizer Inc.
$51.34 (1.31%) $0.67
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$78.08 (1.51%) $1.17
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$300.53 (0.38%) $1.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.